165 related articles for article (PubMed ID: 24270241)
1. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts.
Bhatt MA; Messer A; Kordower JH
J Parkinsons Dis; 2013; 3(4):581-91. PubMed ID: 24270241
[TBL] [Abstract][Full Text] [Related]
2. Intrabodies as neuroprotective therapeutics.
Messer A; Joshi SN
Neurotherapeutics; 2013 Jul; 10(3):447-58. PubMed ID: 23649691
[TBL] [Abstract][Full Text] [Related]
3. (De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants.
Loureiro JA; Andrade S; Goderis L; Gomez-Gutierrez R; Soto C; Morales R; Pereira MC
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830391
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to counter protein aggregation pathology in Parkinson's disease.
Stott SRW; Wyse RK; Brundin P
Prog Brain Res; 2020; 252():451-492. PubMed ID: 32247372
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
7. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
8. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
10. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
[TBL] [Abstract][Full Text] [Related]
13. Intrabody and Parkinson's disease.
Zhou C; Przedborski S
Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
[TBL] [Abstract][Full Text] [Related]
14. Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains.
van Horssen J; de Vos RA; Steur EN; David G; Wesseling P; de Waal RM; Verbeek MM
J Alzheimers Dis; 2004 Oct; 6(5):469-74. PubMed ID: 15505367
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and Neurotherapeutic Effects of Tetrahedral Framework Nucleic Acids on Parkinson's Disease
Cui W; Zhan Y; Shao X; Fu W; Xiao D; Zhu J; Qin X; Zhang T; Zhang M; Zhou Y; Lin Y
ACS Appl Mater Interfaces; 2019 Sep; 11(36):32787-32797. PubMed ID: 31424187
[TBL] [Abstract][Full Text] [Related]
16. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
17. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
Braak H; Sandmann-Keil D; Gai W; Braak E
Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
[TBL] [Abstract][Full Text] [Related]
18. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.
Luk KC; Song C; O'Brien P; Stieber A; Branch JR; Brunden KR; Trojanowski JQ; Lee VM
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20051-6. PubMed ID: 19892735
[TBL] [Abstract][Full Text] [Related]
19. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
Xu Y; Zhang Y; Quan Z; Wong W; Guo J; Zhang R; Yang Q; Dai R; McGeer PL; Qing H
Neurochem Res; 2016 Oct; 41(10):2788-2796. PubMed ID: 27364962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
